Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Three new ABPI company members in 2008

This article was originally published in Scrip

Executive Summary

Three pharmaceutical companies, Merz Pharma, Alexion Pharmaceuticals and Basilea Pharmaceuticals, have become full members of the Association of the British Pharmaceutical Industry(ABPI) so far this year, taking the total number of new members, including general affiliate members, up to 16. New affiliate members include Advocate, a healthcare policy and public affairs consultancy, Vybrant Organisation, which provides training programmes to the pharmaceutical sector, the law firm Bristows, the recruitment firm Heidrick & Struggles, the chartered accountants Rawlinson & Hunter, the consultancies Ernst & Young and LEK Consulting, andTakeda Pharmaceuticals.

You may also be interested in...



Botox shows hope in chronic migraine

Cerimon receives positive Phase II data on diclofenac patch

Cerimon Pharmaceuticals' once-daily topical-patch formulation of the NSAID diclofenac gave significantly better average pain relief than placebo in ankle-sprain patients who carried out their daily activities in a Phase II trial, at the third day in the study.

Lilly's Alimta among SMC's September recommendations

Following a second resubmission, the Scottish Medicines Consortiumhas accepted Lilly's Alimta (pemetrexed) for restricted use within the Scottish NHS as a monotherapy for the second-line treatment of locally advanced or metastatic non-small cell lung cancer.

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC031573

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel